Eli Lilly and Company

LLY

$769.79B

Mega Cap

NYSEPharmaceutical PreparationsPharmaceutical🇺🇸North AmericaINDIANAPOLIS47.0K employees

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

Website

Drugs in Pipeline

376

Phase 3 Programs

211

Upcoming Catalysts

Next Catalyst

Apr 10, 2026

13d

Market Overview

Stock performance and key metrics

LLY News

Catalyst Timeline

40 upcoming, 3 past

PDUFANext

FDA PDUFA Date - Orforglipron

Apr 1, 2026ConfirmedOrforglipron

For obesity. Eli Lilly announced a $3B investment in China to boost supply of Orforglipron, an oral obesity drug under FDA review with a decision expected in April 2026, while also pursuing marketing authorization in China.

Other

Apr 10, 2026AI-detected

Article poses a question about buying Eli Lilly stock before April 10, 2026, but provides no specific news, catalysts, or material information about the company.

38 more catalysts beyond 14 days

Start a 48h free trial to see all upcoming catalysts

Pro

Drug Pipeline

venlafaxine

Drug Name	Phase	Indication	Designations	Patent
venlafaxine	Phase 3	Anxiety Disorders	-	-
Testosterone Solution	Phase 3	Hypogonadism	-	-
Pregabalin	Phase 3	Diabetic Neuropathy, Painful	-	-
teriparatide	Phase 3	Osteoporosis, Postmenopausal	-
Letrozole	Phase 3	Breast Cancer	-	-
Necitumumab	Phase 3	Solid Tumors	-	-
Ixekizumab 80 mg Q4W	Phase 3	Psoriatic Arthritis	-	-
enzastaurin	Phase 3	Non-Small Cell Lung Cancer	-	-
Paclitaxel	Phase 3	Non Small Cell Lung Cancer	-	-
Folinic acid	Phase 3	Colorectal Carcinoma	-	-
Arzoxifene	Phase 3	Osteoporosis, Postmenopausal	-	-
Mirikizumab	Phase 3	Ulcerative Colitis	-	-
Insulin Lispro	Phase 3	Type 2 Diabetes Mellitus	-	-
Insulin Efsitora Alfa	Phase 3	Type 2 Diabetes	-	-
Capecitabine	Phase 3	Metastatic Gastric Adenocarcinoma	-	-
Liraglutide	Phase 3	Type 2 Diabetes Mellitus	-	-
irinotecan	Phase 3	Metastatic Colorectal Cancer	-	-
Tadalafil	Phase 3	Benign Prostatic Hyperplasia	-	-
Etesevimab	Phase 3	COVID-19	-	-
Human regular U-500 insulin (CSII)	Phase 3	Type 2 Diabetes Mellitus	-	-
carboplatin	Phase 3	Breast Cancer	-	-
Fulvestrant	Phase 3	Breast Neoplasms	-	-
Methylphenidate	Phase 3	Attention Deficit Hyperactivity Disorder	-	-
Abemaciclib	Phase 3	Breast Cancer	-	Patent 2031
somatropin, rDNA origin, for injection	Phase 3	Growth Disorder	-	-
Glargine	Phase 3	Diabetes Mellitus, Type 1	-	-
Ramucirumab	Phase 3	Gastric Adenocarcinoma	-	-
lithium	Phase 3	Manic or Mixed Episode Associated With Bipolar I Disorder	-	-
Paclitaxel (Taxane)	Phase 3	Non-Small-Cell Lung Carcinoma	-	Patent 2034
Rapid-Acting Intramuscular Olanzapine	Phase 3	Schizophrenia	-	-
Olanzapine and Fluoxetine combination (OFC)	Phase 3	Treatment Resistant Depression	-	-
Human Insulin Inhalation Powder	Phase 3	Diabetes Mellitus, Type 2	-	-
Glimepiride	Phase 3	Diabetes Mellitus, Type 2	-	-
Donanemab	Phase 3	Alzheimer Disease	-	-
Imlunestrant	Phase 3	Breast Neoplasms	-	-
sildenafil	Phase 3	Impotence	-	-
Insulin Lispro Protamine Suspension	Phase 3	Diabetes Mellitus, Type 2	-	-
Somatropin	Phase 3	Growth Hormone Deficiency	-	-
Pegilodecakin	Phase 3	Pancreatic Cancer	-	-
Duloxetine (DLX)	Phase 3	Osteoarthritis Knee Pain	-	-
Secukinumab	Phase 3	Psoriasis	-	-
Duloxetine Hydrochloride (HCI)	Phase 3	Multiple Sclerosis	-	-
Nasal Glucagon	Phase 3	Hypoglycemia	-	-
dexamethasone	Phase 3	Non Small Cell Lung Cancer	-	Patent 2041
Ultra-Rapid Lispro	Phase 3	Type 1 Diabetes Mellitus	-	-
Retatrutide	Phase 3	Obesity	-	-
Paroxetine	Phase 3	Major Depressive Disorder	-	-
Exemestane	Phase 3	Breast Neoplasms	-
LY3819253	Phase 3	COVID-19	-	-
Detemir	Phase 3	Diabetes Mellitus Type 2	-	-
Galunisertib	Phase 3	Glioblastoma	-	-
prednisone	Phase 3	Prostate Cancer	-	-
Humalog Mix 50	Phase 3	Diabetes Mellitus, Type 1	-	-
Lasmiditan	Phase 3	Migraine	-	-
Insulin Glargine	Phase 3	Diabetes Mellitus, Type 2	-	-
Aducanumab	Phase 3	Mild Cognitive Impairment (MCI)	-	-
docetaxel	Phase 3	Non-Small Cell Lung Cancer	-	-
Olanzapine Hydrochloride	Phase 3	Bipolar Disorder	-	-
LY2216684 (edivoxetine)	Phase 3	Depressive Disorder, Major	-	-
Oral antihyperglycemics	Phase 3	Diabetes Mellitus	-	-
Raloxifene	Phase 3	Vasomotor Symptoms	-	-
LY900014	Phase 3	Type 1 Diabetes Mellitus	-	-
simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder	Phase 3	Diabetes Mellitus, Type 2	-	-
Duloxetine hydrochloride - 40 mg	Phase 3	Diabetic Neuropathies	-	-
tadalafil once a day [T(OaD)]	Phase 3	Erectile Dysfunction	-	-
Biguanides (BG)	Phase 3	Type 2 Diabetes Mellitus	-	-
Exenatide	Phase 3	Diabetes Mellitus, Type 2	-	-
Duloxetine hydrochloride	Phase 3	Diabetic Neuropathy, Painful	-	-
Oral Olanzapine	Phase 3	Schizophrenic Disorders	-	-
Tirzepatide Dose 1	Phase 3	Type2 Diabetes	-	-
semagacestat	Phase 3	Alzheimer's Disease	-	-
Abiraterone	Phase 3	Prostatic Neoplasms	-	-
Gemcitabine	Phase 3	Non-Small Cell Lung Cancer	-	-
Intramuscular Glucagon	Phase 3	Diabetes Mellitus, Type 1	-	-
LY450139	Phase 3	Alzheimer's Disease	-	-
Oral Antihyperglycemic Medications (OAMs)	Phase 3	Type 2 Diabetes Mellitus	-	-
lomustine	Phase 3	Glioblastoma	-	-
oxaliplatin	Phase 3	Colorectal Cancer	-	-
atomoxetine 0.5 mg/kg/day	Phase 3	Attention Deficit Hyperactivity Disorder	-	-
Insulin Lispro 6 Day (6D)	Phase 3	Diabetes Mellitus, Type 1	-	-
Remternetug	Phase 3	Alzheimer's Disease	-	-
Etanercept	Phase 3	Plaque Psoriasis	-	-
80 mg ixekizumab	Phase 3	Psoriasis	-	-
Fluoxetine	Phase 3	Major Depressive Disorder	-	-
Orforglipron	Phase 3	Obesity	-	-
Insulin Degludec	Phase 3	Type 2 Diabetes Mellitus	-	-
Vepugratinib	Phase 3	Carcinoma, Transitional Cell	-	-
Methotrexate	Phase 3	Arthritis, Rheumatoid	-	-
LANTUS®	Phase 3	Diabetes Mellitus, Type 2	-	-
Ruboxistaurin mesylate	Phase 3	Diabetic Neuropathies	-	-
Insulin lispro mix 25	Phase 3	Diabetes Mellitus Type 2	-	-
cDMARD	Phase 3	Rheumatoid Arthritis	-	-
Methylphenidate Hydrochloride	Phase 3	Attention Deficit Hyperactivity Disorder	-	-
solanezumab	Phase 3	Alzheimer's Disease	-	-
Finasteride	Phase 3	Benign Prostatic Hyperplasia	-	-
gemcitabine hydrochloride	Phase 3	Breast Cancer	-	-
Glucagon Nasal Powder	Phase 3	Diabetes Mellitus	-	-
Adalimumab	Phase 3	Rheumatoid Arthritis	-	-
Lasmiditan 50 mg	Phase 3	Migraine With or Without Aura	-	-
Galcanezumab 300 mg	Phase 3	Chronic Cluster Headache	-	-
Standard Adjuvant Endocrine Therapy	Phase 3	Breast Cancer	-	-
Anastrozole	Phase 3	Breast Cancer	-	-
LY2963016	Phase 3	Type 1 Diabetes	-	-
Insulin Lispro Protamine Suspension (ILPS)	Phase 3	Diabetes Mellitus, Type 2	-	-
Alendronate Sodium	Phase 3	Osteoporosis	-	-
Oral antihyperglycemic medication (OAM)	Phase 3	Type 2 Diabetes Mellitus	-	-
Ixekizumab Auto-Injector	Phase 3	Plaque Psoriasis	-	-
Muvalaplin	Phase 3	Elevated Lp(a)	-	-
Tadalafil 5 mg	Phase 3	Benign Prostatic Hyperplasia (BPH)	-	-
Folic Acid	Phase 3	Non Small Cell Lung Cancer	-	-
Human Insulin NPH	Phase 3	Diabetes Mellitus, Type 2	-	-
Drotrecogin alfa (activated)	Phase 3	Sepsis	-	-
Ustekinumab	Phase 3	Plaque Psoriasis	-	-
Vinorelbine	Phase 3	Lung Neoplasms	-	-
cetuximab	Phase 3	Colorectal Neoplasms	-	-
pemetrexed	Phase 3	Non-Small Cell Lung Cancer	-	Patent 2036
Erlotinib	Phase 3	Non Small Cell Lung Cancer	-	-
80 mg Ixekizumab Dosing Regimens 1, 2, and 3	Phase 3	Psoriasis	-	-
etoposide	Phase 3	Non-small Cell Lung Cancer	-	-
insulin lispro injection [rDNA origin] Low Mix	Phase 3	Type 2 Diabetes Mellitus	-	-
Ramucirumab (IMC-1211B) DP	Phase 3	Gastric Cancer	-	-
Clopidogrel	Phase 3	Acute Coronary Syndrome	-	-
Prasugrel	Phase 3	Sickle Cell Anemia	-	-
Commercially-available Aspirin	Phase 3	Acute Coronary Syndrome	-	-
Lepodisiran Sodium	Phase 3	Atherosclerotic Cardiovascular Disease (ASCVD)	-	-
Fumaric Acid Esters	Phase 3	Plaque Psoriasis	-	-
Testosterone MD-Lotion	Phase 3	Hypogonadism	-	-
Raloxifene HCL	Phase 3	Osteoporosis, Postmenopausal	-	-
Salmon Calcitonin	Phase 3	Osteoporosis	-	-
LY3537031	Phase 3	Alcohol Use Disorder	-	-
Calcium Supplement	Phase 3	Osteoporosis, Postmenopausal	-	-
[Lu-177]-PNT2002	Phase 3	Metastatic Castration-Resistant Prostate Cancer	-	-
Eloralintide	Phase 3	Overweight	-	-
Abiraterone acetate	Phase 3	Prostate Cancer	-	-
Risedronate	Phase 3	Osteoporosis	-	-
Ramucirumab (IMC-1121B)	Phase 3	Breast Cancer	-	-
Lebrikizumab Pen	Phase 3	Atopic Dermatitis	-	-
LY4064809	Phase 3	Breast Neoplasms	-	-
5-Fluorouracil	Phase 3	Head and Neck Cancer	-	-
GEMZAR	Phase 3	Pancreatic Neoplasms	-	-
Selpercatinib	Phase 3	Non-Small Cell Lung Cancer	-	-
Pembrolizumab	Phase 3	Carcinoma, Non-Small-Cell Lung	-	-
ERA as specific PAH treatment	Phase 3	Hypertension, Pulmonary	-	-
tamoxifen	Phase 3	Metastatic Breast Cancer	-	-
Escitalopram	Phase 3	Major Depressive Disorder	-	-
Haloperidol	Phase 3	Schizophrenia	-	-
Semaglutide	Phase 3	Type 2 Diabetes	-	-
Dulaglutide	Phase 3	Type 2 Diabetes Mellitus	-	-
Duloxetine 60 mg	Phase 3	Fibromyalgia	-	-
Topical corticosteroid	Phase 3	Atopic Dermatitis	-	-
Olomorasib	Phase 3	Carcinoma, Non-Small-Cell Lung	-	-
Mirikizumab SC	Phase 3	Ulcerative Colitis	-	-
Insulin Lispro (U100)	Phase 3	Type 2 Diabetes	-	-
Intramuscular Olanzapine Depot	Phase 3	Schizophrenia	-	-
Insulin lispro 2 day reservoir in-use	Phase 3	Diabetes Mellitus, Type 1	-	-
injected insulin	Phase 3	Diabetes Mellitus	-	-
Insulin Levemir	Phase 3	Diabetes Mellitus, Type 1	-	-
Bamlanivimab	Phase 3	COVID-19	-	-
olanzapine pamoate depot	Phase 3	Schizophrenia	-	-
Mirikizumab IV	Phase 3	Ulcerative Colitis	-	-
Olaratumab	Phase 3	Metastatic Pancreatic Cancer	-	-
Metformin	Phase 3	Type 2 Diabetes Mellitus	-	-
LY2062430	Phase 3	Alzheimer's Disease	-	-
Other standard therapy for ADHD	Phase 3	Attention Deficit Hyperactivity Disorder	-	-
teriparatide 20 micrograms/day subcutaneous	Phase 3	Osteoporosis, Post-Menopausal	-	-
salmon calcitonin 100 IU/day subcutaneous	Phase 3	Osteoporosis, Post-Menopausal	-	-
Nasal Glucagon (NG)	Phase 3	Drug-specific Antibodies	-	-
Standard therapy for INCS	Phase 3	Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)	-	-
Atomoxetine Hydrochloride	Phase 3	Attention Deficit Hyperactivity Disorder	-
Lantus	Phase 3	Diabetes Mellitus, Type 2	-	-
LY2605541	Phase 3	Type 1 Diabetes Mellitus	-	-
Neutral protamine hagedorn insulin	Phase 3	Diabetes Mellitus, Type 2	-	-
Lasmiditan 100 mg	Phase 3	Acute Migraine	-	-
liposomal doxorubicin	Phase 3	Genital Neoplasms, Female	-	-
Gefitinib	Phase 3	Non Small Cell Lung Cancer	-	-
Baricitinib	Phase 3	Systemic Juvenile Idiopathic Arthritis	-	Patent 2032
80 mg ixekizumab Dosing Regimen	Phase 3	Psoriasis	-	-
cisplatin	Phase 3	Non-Small Cell Lung Cancer	-
Galcanezumab	Phase 3	Chronic Migraine	-	-
Ethinyl estradiol	Phase 3	Turner Syndrome	-	-
Ixekizumab	Phase 3	Psoriasis	-	-
Tirzepatide	Phase 3	Overweight	-	Patent 2041
dirucotide	Phase 3	Secondary Progressive Multiple Sclerosis	-	-
Insulin Aspart	Phase 3	Type 2 Diabetes Mellitus	-	-
Ramucirumab DP (IMC-1121B)	Phase 3	Hepatocellular Carcinoma	-	-
Injectable insulin	Phase 3	Diabetes Mellitus, Type 2	-	-
5 mg Tadalafil	Phase 3	Benign Prostate Hyperplasia	-	-
Dapagliflozin	Phase 3	Type 2 Diabetes	-	-
BEC2 Vaccine	Phase 3	Carcinoma, Small Cell Lung	-	-
Lebrikizumab	Phase 3	Atopic Dermatitis	-	-
LY3537982	Phase 3	Carcinoma, Non-Small-Cell Lung	-	-
SSRI	Phase 3	Major Depressive Disorder	-	-
amantadine	Phase 3	Schizophrenia	-	-
leuprorelin	Phase 3	Idiopathic Short Stature (ISS)	-	-
Insulin	Phase 3	Diabetes Mellitus, Type 2	-	-
Sofetabart Mipitecan	Phase 3	Ovarian Neoplasms	-	-
Atomoxetine	Phase 3	Attention Deficit Hyperactivity Disorder	-	-
Remternetug (IV)	Phase 3	Alzheimer's Disease	-	-
Duloxetine	Phase 3	Urinary Stress Incontinence	-	-
Doxorubicin	Phase 3	Breast Cancer	-	-
LY353381	Phase 3	Breast Neoplasms	-	-
LY2216684	Phase 3	Major Depressive Disorder	-	-
Insulin Peglispro	Phase 3	Type 2 Diabetes Mellitus	-	-
Somatropin (rDNA origin) for injection	Phase 3	Failure to Thrive	-	-
Rapid Acting Intramuscular Olanzapine	Phase 3	Schizophrenia	-	-
LY3650150	Phase 3	Perennial Allergic Rhinitis (PAR)	-	-
LY2189265	Phase 3	Diabetes Mellitus, Type 2	-	-
Sulfonylureas (SU)	Phase 3	Type 2 Diabetes Mellitus	-	-
50 mg etanercept	Phase 3	Psoriasis	-	-
olanzapine	Phase 3	Bipolar Disorder I or II	-
LY2127399	Phase 3	Arthritis, Rheumatoid	-	-
Atorvastatin	Phase 2	Dyslipidemias	-	-
Erbitux (Cetuximab)	Phase 2	Colorectal Neoplasms	-	-
LY2140023	Phase 2	Schizophrenia	-	-
LY3209590	Phase 2	Type 2 Diabetes Mellitus	-	-
IMC-1121B (ramucirumab)	Phase 2	Carcinoma, Non-Small-Cell Lung	-	-
LY3016859	Phase 2	Osteoarthritis	-	-
MORF-057	Phase 2	Inflammatory Bowel Diseases	-	-
Prexasertib	Phase 2	Ovarian Cancer	-	-
LY2409021	Phase 2	Diabetes Mellitus, Type 2	-	-
LY3473329	Phase 2	Lipoprotein Disorder	-	-
LY517717	Phase 2	Total Knee Replacement	-	-
LY3857210	Phase 2	Diabetic Peripheral Neuropathic Pain	-	-
120 mg LY2784544	Phase 2	Neoplasms, Hematologic	-	-
Cixutumumab	Phase 2	Non-Small-Cell Lung Carcinoma	-	-
LY2189102	Phase 2	Arthritis, Rheumatoid	-	-
LY3451838	Phase 2	Migraine	-	-
Tadalafil 2.5 mg	Phase 2	Benign Prostatic Hyperplasia	-	-
Platinol	Phase 2	Carcinoma, Transitional Cell	-	-
Brenipatide	Phase 2	Asthma	-	-
LY2623091	Phase 2	Primary Hypertension	-	-
LY3938577	Phase 2	Diabetes Mellitus, Type 2	-	-
LY2428757	Phase 2	Diabetes Mellitus, Type 2	-	-
LOXO-292	Phase 2	Medullary Thyroid Cancer	-	-
olanzapine-RAIM	Phase 2	Schizophrenia	-	-
Tadalafil- Tablet or Oral suspension	Phase 2	Pulmonary Arterial Hypertension	-	-
LY3023414	Phase 2	Prostate Cancer Metastatic	-	-
LY3561774	Phase 2	Dyslipidemias	-	-
LY3848575	Phase 2	Neuropathic Pain	-	-
Mevidalen	Phase 2	Alzheimer Disease	-	-
ALIMTA	Phase 2	Colorectal Cancer	-	-
Bimagrumab	Phase 2	Obesity	-	-
LY2603618	Phase 2	Non Small Cell Lung Cancer	-	-
LY2439821	Phase 2	Rheumatoid Arthritis	-	-
Emibetuzumab	Phase 2	Carcinoma, Non-Small-Cell Lung	-	-
Testosterone Solution 2%	Phase 2	Ejaculatory Dysfunction	-	-
Cetuximab + platinum + gemcitabine	Phase 2	Non-Small-Cell Lung Carcinoma	-	-
Cyclophosphamide	Phase 2	Desmoplastic Small Round Cell Tumor	-	-
Ramucirumab DP	Phase 2	Carcinoma of Urinary Tract	-	-
LY545694 49 mg	Phase 2	Osteoarthritis Knee Pain	-	-
LY2181308 sodium	Phase 2	Prostate Cancer	-	-
LY3819469	Phase 2	Lipoprotein Disorder	-	-
LY686017	Phase 2	Social Phobia	-	-
LY573636-sodium	Phase 2	Ovarian Cancer	-	-
Zagotenemab	Phase 2	Alzheimer Disease (AD)	-	-
STX-478	Phase 2	Breast Cancer	-	-
LY2452473	Phase 2	Erectile Dysfunction	-	-
LY3305677	Phase 2	Obesity	-	-
LY450139 dihydrate	Phase 2	Alzheimer's Disease	-	-
LY2196044	Phase 2	Alcohol Dependence	-	-
LY3009104	Phase 2	Arthritis, Rheumatoid	-	-
IMC-A12 (Cixutumumab)	Phase 2	Adenocarcinoma of the Prostate	-	-
LY2090314	Phase 2	Leukemia	-	-
Eltrekibart	Phase 2	Hidradenitis Suppurativa	-	-
Temozolomide	Phase 2	Sarcoma, Ewing	-	-
Bortezomib	Phase 2	Multiple Myeloma	-	-
Sunitinib	Phase 2	Metastatic Renal Cell Carcinoma	-	-
Leucovorin (LV)	Phase 2	Colorectal Cancer	-	-
Pemetrexed Phase 1	Phase 2	Non-Small Cell Lung Cancer	-	-
LY3462817	Phase 2	Rheumatoid Arthritis	-	-
LY3015014	Phase 2	Hypercholesterolemia	-	-
LY2624803	Phase 2	Primary Insomnia	-	-
Mibavademab	Phase 2	Obesity	-	-
LY3972406	Phase 2	Plaque Psoriasis	-	-
Loperamide	Phase 2	Breast Cancer	-	-
LY3841136	Phase 2	Obesity	-	-
Leucovorin	Phase 2	Stomach Cancer	-	-
LY3039478	Phase 2	T-cell Acute Lymphoblastic Leukemia	-	-
LY3437943	Phase 2	Obesity	-	-
LY2510924	Phase 2	Extensive Stage Small Cell Lung Carcinoma	-	-
LY293111	Phase 2	Pancreatic Cancer	-	-
LY2828360	Phase 2	Osteoarthritis, Knee	-	-
Prasugrel (CS-747)	Phase 2	Cardiovascular Diseases	-	-
sPLA2 Inhibitor	Phase 2	Sepsis	-	-
LY3526318	Phase 2	Chronic Low-back Pain	-	-
LY2495655	Phase 2	Pancreatic Cancer	-	-
IMC-1121B	Phase 2	Cancer	-	-
LY3202626	Phase 2	Alzheimer Disease	-	-
Pemetrexed 500 mg/m2	Phase 2	Non-small Cell Lung Cancer	-	-
IMC-18F1	Phase 2	Breast Cancer	-	-
PPAR alpha	Phase 2	Hypercholesterolemia	-	-
5 - FU	Phase 2	Solid Tumor	-	-
LY3154207	Phase 2	Lewy Body Dementia	-	-
arzoxifene hydrochloride	Phase 2	Endometrial Cancer	-	-
Triamcinolone (Optional)	Phase 2	Atopic Dermatitis	-	-
depot octreotide	Phase 2	Carcinoma	-	-
Subcutaneous Teriparatide	Phase 2	Osteoporosis	-	-
LY3556050	Phase 2	Diabetic Peripheral Neuropathy	-	-
Dacarbazine	Phase 2	Metastatic Malignant Melanoma	-	-
LY3871801	Phase 2	Rheumatoid Arthritis	-	-
LY2157299	Phase 2	Hepatocellular Carcinoma	-	-
LY2181308	Phase 2	Non-small Cell Lung Cancer	-	-
tasisulam	Phase 2	Metastatic Melanoma	-	-
LY3502970	Phase 2	Obesity	-	-
LY2541546	Phase 2	Osteoporosis	-	-
S-1	Phase 2	Metastatic Gastric Adenocarcinoma	-	-
LY2228820	Phase 2	Epithelial Ovarian Cancer	-	-
mitomycin C	Phase 2	Superficial Bladder Cancer	-	-
LY3295668	Phase 2	Neoplasms	-	-
LY2523355	Phase 2	Metastatic Breast Cancer	-	-
Enoxaparin	Phase 2	Submassive Pulmonary Embolism	-	-
Sivelestat	Phase 2	Respiratory Distress Syndrome, Adult	-	-
Icrucumab	Phase 2	Colon Cancer	-	-
Hydrochlorothiazide	Phase 2	Mild Hypertension	-	-
Herceptin	Phase 2	Breast Cancer	-	-
LY900003	Phase 2	Carcinoma, Non-Small-Cell Lung	-	-
Pemetrexed - Phase 1	Phase 2	Ovarian Cancer	-	-
LY3041658	Phase 2	Hidradenitis Suppurativa	-	-
cytarabine	Phase 2	Acute Myeloid Leukemia	-	-
LY4268989	Phase 2	Ulcerative Colitis	-	-
LY4100511	Phase 2	Plaque Psoriasis	-	-
LY2484595	Phase 2	Dyslipidemia	-	-
DC-806	Phase 2	Plaque Psoriasis	-	-
Granulocyte colony-stimulating factor (G-CSF)	Phase 2	Small Cell Lung Cancer	-	-
avastin	Phase 2	Colorectal Cancer	-	-
LY2951742	Phase 2	Migraine Headache	-	-
Enzyme-inducing antiepileptic drugs (EIAED)	Phase 2	Recurrent Glioblastoma	-	-
Mitoxantrone	Phase 2	Prostate Cancer	-	-
LY4065967	Phase 2	Diabetic Peripheral Neuropathic Pain	-	-
LY3457263	Phase 2	Type 2 Diabetes	-	-
Solbinsiran	Phase 2	Severe Hypertriglyceridemia	-	-
Dinutuximab	Phase 2	Relapsed Solid Tumor	-	-
LY451395	Phase 2	Alzheimer's Disease	-	-
LY3016859 ISA	Phase 2	Osteoarthritis, Knee	-	-
LOXO-305	Phase 2	Leukemia, Lymphoid	-	-
LY317615	Phase 2	Non-Hodgkin's Lymphoma	-	-
Enzastaurin 500 milligram (mg) Once Daily (QD)	Phase 2	Glioblastoma Multiforme	-	-
naveglitazar	Phase 2	Diabetes Mellitus, Non-Insulin-Dependent	-	-
Mazdutide	Phase 2	Alcohol Use Disorder	-	-
Macupatide	Phase 2	Obesity	-	-
LY2875358	Phase 2	Carcinoma, Non-Small-Cell Lung	-	-
Merestinib	Phase 2	Biliary Tract Cancer	-	-
Pemetrexed (Alimta) in combination with gemcitabine (Gemzar)	Phase 2	Carcinoma, Non-Small-Cell Lung	-	-
LY3541860	Phase 2	Rheumatoid Arthritis	-	-
5 - Fluorouracil	Phase 2	Solid Tumor	-	-
LY3537021	Phase 2	Nausea	-	-
Nab-Paclitaxel	Phase 2	Carcinoma, Non-Small Cell Lung Cancer (NSCLC)	-	-
prasugrel 10 mg	Phase 2	Coronary Arteriosclerosis	-	-
LY041001 (HIIP)	Phase 2	Diabetes Mellitus, Type 2	-	-
IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)	Phase 2	Hepatocellular Carcinoma	-	-
LY3372689	Phase 2	Alzheimer Disease	-	-
Tamsulosin	Phase 2	Benign Prostatic Hyperplasia	-	-
LY3023703	Phase 2	Acute Pain	-	-
pegfilgrastim	Phase 2	Ovarian Cancer	-	-
Prophylactic Loperamide	Phase 2	Metastatic Breast Cancer	-	-
LY2189265 and Lifestyle Measures	Phase 2	Diabetes Mellitus, Type 2	-	-
Standard of Care Single Agent Chemotherapy	Phase 2	Hormone Receptor Positive Breast Cancer	-	-
Nasal Glucagon 1 mg	Phase 2	Hypoglycemia	-	-
Buprenorphine	Phase 2	Opioid Use Disorder	-	-
LY3549492	Phase 2	Obesity	-	-
Eplerenone	Phase 2	Chronic Kidney Disease	-	-
Sorafenib	Phase 2	Carcinoma, Hepatocellular	-	-
Radiation	Phase 2	Glioma	-	-
Enzastaurin Hydrochloride	Phase 2	Breast Neoplasms	-	-
Cetuximab:	Phase 2	Ovarian Cancer	-	-
LY2422347	Phase 2	Sleep Initiation and Maintenance Disorders	-	-
Enzastaurin HCL	Phase 2	Non-Small-Cell Lung Carcinoma	-	-
IMC-A12	Phase 2	Prostate Cancer	-	-
human insulin inhalation powder (HIIP)	Phase 2	Diabetes Mellitus, Type 1	-	-
Risperidone	Phase 2	Schizophrenia	-	-
IMC-11F8 (necitumumab)	Phase 2	Metastatic Colorectal Cancer	-	-
vincristine	Phase 2	Lymphoma	-	-
ALIMTA plus Epirubicin	Phase 2	Breast Cancer	-	-
Pirtobrutinib	Phase 2	Lymphoma, Non-Hodgkin	-	-
cetuximab (Erbitux ®)	Phase 2	Head and Neck Cancer	-	-
Pemetrexed - Before Protocol Amendment	Phase 2	Non Small Cell Lung Cancer	-	-

Eli Lilly and Company

Market Overview

LLY News

Catalyst Timeline

FDA PDUFA Date - Orforglipron

Other

Pipeline & FDA Submissions

Competitive Positions

AI Predictions & Institutional Flow

Market Intelligence

Regulatory Approvals